Impact of Dual Interleukin-17A and Interleukin-17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open-Label Extension.

Bimzelx (bimekizumab-bkzx) - UCB

http://www.ncbi.nlm.nih.gov/pubmed/42740449

Alexander Marten; Chetan Prajapati; Denis Poddubnyy; Mikkel Østergaard; Natasha de Peyrecave; Robert G W Lambert; Sofia Ramiro; Tom Vaux; Ute Massow; Walter P Maksymowych; Xenofon Baraliakos

Sep 16, 2026